华兰生物(002007.SZ)：HL08收到药物临床试验批准通知书

Core Viewpoint - The company, Hualan Biological (002007.SZ), has received approval from the National Medical Products Administration for its drug, HL08, a new generation GLP-1 receptor agonist developed in-house [1] Group 1: Drug Development - HL08 is a recombinant Exendin-4-Fc fusion protein injection [1] - The active ingredient of HL08 is a recombinant Exendin-4-Fc fusion protein, which combines Exendin-4 with the Fc fragment of IgG2 antibody [1] - The drug significantly extends the biological half-life while retaining the natural physiological functions of Exendin-4, enhancing medication convenience and therapeutic efficacy [1]